MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension.

[3] On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales.

On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi.

[7] The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours.

Company founder Alfred Mann stepped in as interim CEO on November 19, 2015.